- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT05981846
Badanie fazy II mające na celu ocenę bezpieczeństwa i immunogenności szczepionki BIMERVAX® podawanej jednocześnie ze szczepionką przeciw grypie sezonowej (SIIV) osobom dorosłym w wieku powyżej 65 lat w pełni zaszczepionym przeciwko COVID-19
Randomizowane, podwójnie ślepe, wieloośrodkowe badanie fazy II oceniające bezpieczeństwo i immunogenność szczepionki BIMERVAX® podawanej jednocześnie z sezonowym antygenem powierzchniowym, inaktywowaną szczepionką przeciw grypie z adiuwantem (SIIV) u osób dorosłych w wieku powyżej 65 lat w pełni zaszczepionych przeciwko COVID -19
This is a Phase II, randomized, double-blind, multi-centre trial to evaluate the safety and immunogenicity of BIMERVAX® when coadministered with seasonal surface antigen inactivated adjuvanted influenza vaccine (SIIV) in adults older than 65 years of age fully vaccinated against COVID-19.
Przegląd badań
Status
Warunki
Interwencja / Leczenie
Szczegółowy opis
This is a Phase II, randomized, double-blind, multi-centre trial to evaluate the safety and immunogenicity of BIMERVAX® when coadministered with seasonal surface antigen inactivated adjuvanted influenza vaccine (SIIV) in adults older than 65 years of age fully vaccinated against COVID-19.
In this study approximately 300 adults aged 65 or older will be enrolled and followed for 1 month after study treatment. Safety and immunogenicity of all participants will be assessed.
The participants will be randomised 1:1:1 to one of the following three cohorts:
- Cohort 1: approximately 100 participants will receive one dose of SIIV in one arm + one dose of placebo in the other arm, at Day 0.
- Cohort 2: approximately 100 participants will receive one dose of BIMERVAX® in one arm + 1 dose of placebo in the other arm, at Day 0.
- Cohort 3: approximately 100 participants will receive one dose SIIV in one arm + one dose of BIMERVAX® in the other arm, at Day 0.
All participants will receive two administrations at Day 0 and will be followed for 1 month. All subjects will be closely observed for 15 minutes after vaccination on site. The study will be double-blind, both the participant and the physician (care provider) will be blinded. Participants will be provided with a participant paper diary on Day 0 to record solicited local and systemic reactions after vaccination through Day 7. Unsolicited local and systemic adverse events, SAEs and AESIs, will be recorded through Day 28 (end of study).
Typ studiów
Zapisy (Rzeczywisty)
Faza
- Faza 2
Kontakty i lokalizacje
Lokalizacje studiów
-
-
A Coruña
-
A Coruña, A Coruña, Hiszpania, 15011
- Hospital HM Modelo
-
Santiago de Compostela, A Coruña, Hiszpania, 15706
- Hospital Clínico Universitario de Santiago
-
-
Barcelona
-
Badalona, Barcelona, Hiszpania, 08916
- Hospital Germans Trias i Pujol
-
Barcelona, Barcelona, Hiszpania, 08036
- Hospital Clínic de Barcelona
-
Centelles, Barcelona, Hiszpania, 08540
- CAP Centelles
-
-
Girona
-
Girona, Girona, Hiszpania, 17001
- Hospital Josep Trueta
-
-
Málaga
-
Málaga, Málaga, Hiszpania, 29010
- Hospital Regional de Málaga
-
-
Valladolid
-
Valladolid, Valladolid, Hiszpania, 47003
- Hospital Clínico de Valladolid
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
-
Adults aged 65 or older at Day 0.
-
Are willing and able to sign the informed consent and can comply with all study visits and procedures.
-
Participant must have received at least a primary scheme of an mRNA vaccine (2 doses). Booster doses or previous COVID-19 infections are allowed. Last dose must have been administered at least 6 months before Day 0. History of COVID-19 infection is allowed if occurred at least >30 days before Day 0.
-
Have a negative Rapid Antigen Test (RAT) at Day 0 before vaccinations.
-
Adults determined by clinical assessment, including medical history and clinical judgement, to be eligible for the study, including adults with pre-existing chronic and stable diseases (non-immunocompromised), if these are stable and well-controlled according to the investigator's judgment.
Exclusion Criteria:
-
Acute illness with fever ≥ 38.0°C at Day 0 or within 24 hours prior to vaccination. Afebrile participants with minor illnesses can be enrolled at the discretion of the investigator.
-
Allergy to egg proteins (egg or egg products) or chicken proteins.
-
History of Guillain-Barré syndrome (GBS)
-
History of COVID-19 infection (described as a positive RAT or PCR), in the previous 30 days before Day 0.
-
Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behaviour that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
-
History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (e.g. anaphylaxis) to any component of the study intervention(s).
-
Immunocompromised individuals defined as those with primary and secondary immune deficiencies and those receiving chemotherapy or immunosuppressant drugs other than steroids and glucocorticoids (maximum 30mg/day of prednisone, or equivalent, by any administration route for a maximum of 30 consecutive days), within 90 days prior to vaccination or during the study.
-
Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection.
-
Receipt of blood-derived immune globulins, blood, or blood-derived products in the past 3 months.
-
Participation in other studies involving study intervention within 28 days prior to screening and/or during study participation.
-
Received any non-study vaccine within 14 days before or after screening. For live or attenuated vaccines, 4 weeks before or after screening.
-
History of a diagnosis or other conditions that, in the judgment of the investigator, may affect study endpoint assessment or compromise participant safety.
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Zapobieganie
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Poczwórny
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Eksperymentalny: BIMERVAX + SIIV
|
One dose of booster vaccine One dose |
|
Aktywny komparator: BIMERVAX + PLACEBO
|
One dose of booster vaccine |
|
Aktywny komparator: SIIV + PLACEBO
|
One dose |
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Number, percentage, and characteristics of solicited local and systemic reactions through Day 7 after vaccination.
Ramy czasowe: Day 0, Day 7
|
To assess and compare the safety and tolerability of BIMERVAX® coadministered with SIIV in adults with respect to each vaccine administered alone. |
Day 0, Day 7
|
|
Number, percentage, and characteristics of unsolicited local and systemic adverse events (AEs) through the end of the study.
Ramy czasowe: Day 0, Day 7, Day 28
|
To assess and compare the safety and tolerability of BIMERVAX® coadministered with SIIV in adults with respect to each vaccine administered alone. |
Day 0, Day 7, Day 28
|
|
Number and percentage of serious adverse events (SAEs) through the end of the study.
Ramy czasowe: Day 0, Day 7, Day 28
|
To assess and compare the safety and tolerability of BIMERVAX® coadministered with SIIV in adults with respect to each vaccine administered alone. |
Day 0, Day 7, Day 28
|
|
Number and percentage of adverse events of special interest (AESI) through the end of the study
Ramy czasowe: Day 0, Day 7, Day 28
|
To assess and compare the safety and tolerability of BIMERVAX® coadministered with SIIV in adults with respect to each vaccine administered alone. |
Day 0, Day 7, Day 28
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Total binding antibody titers against SARS-CoV-2 RBD at Days 0 and 28
Ramy czasowe: Day 0, Day28
|
To determine and compare the immunogenicity measured by means of total antibodies against the Receptor Binding Domain of the Spike protein of SARS-CoV-2, measured by an electrochemiluminescence immunoassay (ECLIA) at Baseline and Day 28, in participants vaccinated with BIMERVAX® alone or coadministered with SIIV. |
Day 0, Day28
|
|
Geometric mean fold rise in total binding antibody titers against SARS-CoV-2 RBD at Day 28
Ramy czasowe: Day 0, Day28
|
To determine and compare the geometric mean fold rise (GMFR) in total binding antibody titers against the Receptor Binding Domain of the Spike protein of SARS-CoV-2 from Baseline to Day 28, in participants vaccinated with BIMERVAX® alone or coadministered with SIIV. |
Day 0, Day28
|
|
Influenza strain-specific HAI antibody titers at Days 0 and 28
Ramy czasowe: Day 0, Day28
|
To determine and compare the immunogenicity measured by influenza strain-specific antibody titers using a haemagglutination inhibition (HAI) assay at Baseline and Day 28, in participants vaccinated with SIIV alone or coadministered with BIMERVAX® |
Day 0, Day28
|
|
Geometric mean fold rise in influenza strain-specific HAI antibody titers at Day 28
Ramy czasowe: Day 0, Day28
|
To determine and compare the geometric mean fold rise (GMFR) in influenza strain-specific antibody titers measured by haemagglutination inhibition (HAI) assay from Baseline to Day 28, in participants vaccinated with SIIV alone or coadministered with BIMERVAX®. |
Day 0, Day28
|
Współpracownicy i badacze
Sponsor
Śledczy
- Dyrektor Studium: Teresa Prat, Hipra Scientific, S.L.U
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Zakończenie podstawowe (Rzeczywisty)
Ukończenie studiów (Rzeczywisty)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
- HIPRA-HH-11
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .